Latest filings (excl ownership)
10-K/A
2023 FY
Annual report (amended)
26 Apr 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
15 Apr 24
8-K
NanoVibronix Issues Letter to Stockholders
9 Apr 24
10-K
2023 FY
Annual report
8 Apr 24
NT 10-K
Notice of late annual filing
1 Apr 24
8-K
NanoVibronix Signs Agreement for Research and Development of Next Generation PainShield and UroShield
28 Mar 24
DEFA14A
Additional proxy soliciting materials
17 Jan 24
8-K
Other Events
17 Jan 24
8-K
Changes in Registrant's Certifying Accountant
11 Dec 23
8-K
Departure of Directors or Certain Officers
4 Dec 23
DEFA14A
Additional proxy soliciting materials
29 Nov 23
DEF 14A
Definitive proxy
29 Nov 23
8-K
NanoVibronix Announces Agreement for Clinical Study of UroShield at the University of Michigan
28 Nov 23
8-K
Other Events
21 Nov 23
8-K
NanoVibronix Issues Letter to Shareholders
14 Nov 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
Receives Stocking Order from U.K. Distribution Partner in Anticipation of Increasing Demand
7 Nov 23
8-K
NanoVibronix Gains Approval for Inclusion of UroShield Products in NHS Prescription Services’ Drug Tariff
27 Sep 23
EFFECT
Notice of effectiveness
22 Sep 23
424B3
Prospectus supplement
21 Sep 23
RW
Registration withdrawal request
21 Sep 23
CORRESP
Correspondence with SEC
19 Sep 23
UPLOAD
Letter from SEC
19 Sep 23
D
$13.55 mm in equity / options / securities to be acquired, sold $13.55 mm, 1 investor
13 Sep 23
S-3
Shelf registration
12 Sep 23
8-K
NanoVibronix Announces Presentation of Positive Independent Testing Results of UroShield at ICS Annual Meeting
6 Sep 23
8-K
NanoVibronix Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
1 Sep 23
8-K
NanoVibronix Cites Positive Results from Independent Testing of UroShield
30 Aug 23
8-K
Regulation FD Disclosure
29 Aug 23
8-K
NanoVibronix Applies for Inclusion of UroShield Products in NHS Prescription Services’ Drug Tariff
28 Aug 23
8-K
NanoVibronix Extends Distribution Agreement with Its Largest Distributor for PainShield and PainShield Plus
23 Aug 23
EFFECT
Notice of effectiveness
14 Aug 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
CORRESP
Correspondence with SEC
9 Aug 23
UPLOAD
Letter from SEC
9 Aug 23
S-1/A
IPO registration (amended)
7 Aug 23
S-3
Shelf registration
1 Aug 23
8-K
Other Events
20 Jul 23
S-1
IPO registration
17 Jul 23
Latest ownership filings
4
THOMAS MIKA
26 Feb 24
4
HAROLD JACOB
26 Feb 24
4
Maria Schroeder
23 Feb 24
4
Michael Ferguson
23 Feb 24
4
Martin M Goldstein
23 Feb 24
4
Aurora Cassirer
23 Feb 24
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 24
4
Brian M Murphy
6 Dec 23
4
CHRISTOPHER M FASHEK
6 Dec 23
4
THOMAS MIKA
4 Dec 23
4
Maria Schroeder
4 Dec 23
4
Martin M Goldstein
4 Dec 23
4
STEPHEN RUSSELL BROWN
4 Dec 23
4
HAROLD JACOB
4 Dec 23
4
Michael Ferguson
4 Dec 23
4
Aurora Cassirer
4 Dec 23
4
THOMAS MIKA
5 Jan 23
4
CHRISTOPHER M FASHEK
17 Jun 22
4
CHRISTOPHER M FASHEK
17 Jun 22
4
STEPHEN RUSSELL BROWN
14 Jun 22
4
Aurora Cassirer
2 Jun 22
3
Maria Schroeder
24 Jan 22
3
Aurora Cassirer
20 Jan 22
4
HAROLD JACOB
3 Jan 22
4
Brian M Murphy
3 Jan 22
4
THOMAS MIKA
3 Jan 22
4
CHRISTOPHER M FASHEK
3 Jan 22
4
STEPHEN RUSSELL BROWN
30 Dec 21
4
Michael Ferguson
30 Dec 21
4
Martin M Goldstein
30 Dec 21
SC 13G/A
KENNEDY CAPITAL MANAGEMENT, INC.
16 Feb 21
SC 13G/A
PACKER PAUL
12 Feb 21
SC 13G/A
HIRSCHMAN ORIN
10 Feb 21
SC 13G/A
ALPHA CAPITAL ANSTALT
19 Jan 21
4
Martin M Goldstein
28 Dec 20
4
Michael Ferguson
28 Dec 20
4
Brian M Murphy
23 Dec 20
4
CHRISTOPHER M FASHEK
23 Dec 20
4
THOMAS MIKA
23 Dec 20
4
STEPHEN RUSSELL BROWN
23 Dec 20